Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: A chart review analysis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 3, 2014, Pages 245-251

  Deangelo, Daniel J ^a   Chen, Lei ^b   Guerin, Annie ^c   Styles, Amy ^c   Giguere Duval, Philippe ^c   Wu, Eric Q ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Chart review; Chronic myelogenous leukemia; Dasatinib; Nilotinib; Treatment response

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; OVERALL SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CHROMOSOME ANALYSIS; GENETICS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; MORTALITY; TIME; TREATMENT FAILURE;

AGED; BENZAMIDES; CYTOGENETIC ANALYSIS; DRUG SUBSTITUTION; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84900008804     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.12.002     Document Type: Article

References (16)

1. S.G. O'Brien, F. Guilhot, and R.A. Larson et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
2. H. Kantarjian, S. O'Brien, and E. Jabbour et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience Blood 119 2012 1981 1987
3. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
4. T.P. Hughes, J. Kaeda, and S. Branford et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432
5. H. Kantarjian, R. Pasquini, and N. Hamerschlak et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial Blood 109 2007 5143 5150
6. H.M. Kantarjian, F. Giles, and N. Gattermann et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 2007 3540 3546
7. Q. Hochhaus, M. Baccarani, and M. Deninger et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Leukemia 22 2008 1200 1206
8. E. Jabbour, H. Kantarjian, and S. O'Brien et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors Blood 118 2011 4541 4546
9. B.J. Druker, F. Guilhot, and S.G. O'Brien et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
10. H. de Lavallade, J.F. Apperley, and J.S. Khorashad et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis J Clin Oncol 26 2008 3358 3363
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia (v2.2012). Available at: http://www.nccn.org. Accessed: December 20, 2013.
12. M. Baccarani, J. Cortes, and F. Pane et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 2009 6041 6051
13. B. Hanfstein, M.C. Müller, and R. Hehlmann et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia Leukemia 26 2012 2096 2102
14. L. Chen, A. Guerin, and J. Xie Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis Curr Med Res Opin 28 2012 1 9
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia (v1.2013). Available at: http://www.nccn.org. Accessed: December 20, 2013.
16. M. Baccarani, M.W. Deininger, and G. Rosti et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 Blood 122 2013 872 884